Therapeutics Acquisition Corp (RACA) to Combine with POINT Biopharma in $639M Deal

Therapeutics Acquisition Corp (RACA) to Combine with POINT Biopharma in $639M Deal

Therapeutics, doing-business-as Research Alliance Corp. I (NASDAQ:RACA), has entered into a definitive agreement to combine with POINT Biopharma at an enterprise value of $639.2 million. POINT is a clinical stage radiopharmaceutical firm researching the use of radioglands to treat cancer before and during chemotherapy. The combined entity is expected to trade on the Nasdaq under
Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.